GlassScriptPhysician profile
Brian J Costleigh
NPI 1932101144
$2,983.40
in general payments reported to CMS, 2019-2025
34 companies · $2,003 in 2025
The $2,003 reported for 2025 was more than what 90% of Radiation Oncology providers received nationally (typical 2025 total: $172).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $305 · 2020: $38.17 · 2021: $61.44 · 2022: $182 · 2023: $226 · 2024: $168 · 2025: $2,003.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,244 · Food and Beverage: $1,153.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,244.24 |
| Food and Beverage | $1,153.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teleflex LLC | $1,850.75 | 2025 | Urolift, Barrigel |
| Astrazeneca Pharmaceuticals LP | $154.38 | 2019-2022 | |
| Boston Scientific Corporation | $108.58 | 2019 | |
| Abbvie INC. | $79.97 | 2019-2025 | |
| Janssen Biotech, INC. | $67.70 | 2022-2023 | Erleada |
| Pfizer INC. | $50.28 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.83 | 2022-2023 | Alunbrig |
| Merck Sharp & Dohme LLC | $47.19 | 2022-2024 | Lynparza, Keytruda |
| Pharmacyclics LLC, An Abbvie Company | $44.24 | 2020-2023 | Imbruvica |
| Seagen INC. | $40.41 | 2023 | Tukysa |
| Incyte Corporation | $37.41 | 2022-2023 | Monjuvi, Jakafi |
| Sun Pharmaceutical Industries INC. | $30.90 | 2025 | |
| Telix Pharmaceuticals | $30.72 | 2025 | |
| Dendreon Pharmaceuticals LLC | $29.25 | 2025 | Provenge |
| Karyopharm Therapeutics INC. | $25.31 | 2024 | Xpovio |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novocure INC. | $24.18 | 2024 | Optune |
| Myovant Sciences INC. | $23.93 | 2021 | |
| Genmab U.S., INC. | $23.09 | 2023 | Tivdak |
| Blueprint Medicines Corporation | $22.55 | 2024 | Ayvakit |
| Alexion Pharmaceuticals, INC. | $22.06 | 2024 | Ultomiris |
| Novartis Pharmaceuticals Corporation | $21.66 | 2020 | |
| Lilly USA, LLC | $20.91 | 2022 | |
| Glaxosmithkline, LLC. | $20.25 | 2021 | |
| Amgen INC. | $17.40 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $17.26 | 2021 | |
| Menarini Silicon Biosystems, INC. | $16.65 | 2025 | |
| Genzyme Corporation | $15.00 | 2023 | |
| Immunocore Limited | $14.24 | 2022 | |
| Clovis Oncology, INC. | $13.79 | 2019 | |
| Morphosys, US INC. | $13.77 | 2023 | Monjuvi |
| Coherus Oncology, INC. | $13.49 | 2022 | |
| Deciphera Pharmaceuticals INC. | $13.29 | 2024 | Qinlock |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.83 | 2019 | |
| Celgene Corporation | $12.13 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Costleigh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.